Terra Wonsettler, PharmD, MBA, vice president of pharmacy for Evolent, discusses the recent HHS OIG report that stemmed from the 2021 FDA approval of aducanumab (Aduhelm) and use of the accelerated approval pathway.
Terra Wonsettler, PharmD, MBA
Advertisement
Articles by Terra Wonsettler, PharmD, MBA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301
2
Cancer’s Hidden Wound: Trauma From Diagnosis Through Survivorship
3
Odronextamab Plus CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Matthew Matasar, MD
4
New French Psoriasis Guidelines Add Biologics, Comorbidity Guidance to Algorithm
5